Search

everythinglearnresearchcommunity

for

Search:↓

Anlotinib combined with taxane/capecitabine is more effective than bevacizumab for treating HER-2 negative metastatic breast cancer.

Adding dutasteride to therapy may improve treatment for advanced salivary duct cancer.

The new chemotherapy combination for advanced lung cancer showed a 35.7% response rate but caused significant side effects.

The drug combination was safe and showed promise in treating advanced tumors.

New treatments are making advanced prostate cancer management more complex but also more hopeful.

Non-hormonal treatments should be used first for sexual dysfunction in postmenopausal breast cancer patients on aromatase inhibitors, with hormones as a second option.

Quality of life, overall survival, and progression-free survival should be equally prioritized in advanced breast cancer treatment decisions.

Carboplatin-paclitaxel is preferred for advanced lung cancer due to its balance of affordability and patient well-being.

The combination of high-dose toremifene and capecitabine was effective for advanced recurrent breast cancer.

Chemoprevention can significantly lower cancer risks and needs more research and collaboration.

Hormone therapy might be a proactive alternative to watchful waiting for early-stage prostate cancer, potentially improving survival without aggressive treatment downsides.

Combining gemcitabine with paclitaxel is more effective than with pemetrexed for advanced lung cancer.

Norethisterone (jenapharm) therapy is effective for endometrial cancer.

Fulvestrant is a well-tolerated new treatment for advanced breast cancer that may delay chemotherapy.

CT-707 is effective and safe for treating certain Chinese lung cancer patients.

Patients with advanced breast cancer prioritize quality of life, overall survival, and progression-free survival in treatment decisions.

Mitoxantrone with a corticosteroid helps manage symptoms for some advanced prostate cancer patients but doesn't extend life.

Further testing of paclitaxel poliglumex for this cancer treatment is not justified.

The treatment was effective and tolerable for advanced gastric cancer.

Temozolomide improves survival in grade III glioma patients without harming quality of life.

Nurses are crucial in managing chemotherapy side effects for ovarian cancer patients to improve their quality of life.

ADCs can effectively treat breast cancer but may cause side effects like nausea and hair loss.

Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.

The treatment is safe and shows promise for metastatic breast cancer.

MK-5108 is safe and shows potential against tumors, especially alone.

Both treatments are similarly effective, but paclitaxel-carboplatin is cheaper and has more severe side effects.

Metyrapone effectively stabilizes severe Cushing's disease symptoms before surgery.

Paclitaxel and nab-paclitaxel can be safe and effective for advanced gastric cancer patients on hemodialysis.

Docetaxel chemotherapy causes more long-term hair loss and dissatisfaction than paclitaxel.